The Liver/NASH
= ILF Board Member Author(s)
.jpg)
Pinolenic acid ameliorates oleic acid-induced lipogenesis and oxidative stress via AMPK/SIRT1 signaling pathway in HepG2 cells
Combination of CCl4 with alcoholic and metabolic injuries mimics human liver fibrosis
Hyperferritinemia in Nonalcoholic Fatty Liver Disease: Iron Accumulation or Inflammation?
Steroid Metabolomic Signature of Liver Disease in Nonsyndromic Childhood Obesity
Therapeutic effects of curcumin and ursodexycholic acid on non-alcoholicfatty liver disease
Incretin‐based Therapies for the Management of NAFLD in Patients with Type 2 Diabetes
Fructose Promotes Leaky Gut, Endotoxemia and Liver Fibrosis through CYP2E1‐Mediated Oxidative and Nitrative Stress
Fetuin-B Links Nonalcoholic Fatty Liver Disease to Chronic Kidney Disease in Obese Chinese Adults: A Cross-Sectional Study
Elevated hepatic MDR3/ABCB4 is directly mediated by MiR-378a-5p in human obstructive cholestasis.
MS-275 induces hepatic FGF21 expression via H3K18ac–mediated CREBH signal
Determination of fasiglifam-induced liver toxicity: Insights from the data monitoring committee of the fasiglifam clinical trials program
Hepatocyte and stellate cell deletion of liver fatty acid binding protein reveals distinct roles in fibrogenic injury
Inhibition of CCL19 benefits non‑alcoholic fatty liver disease by inhibiting TLR4/NF‑κB‑p65 signaling
Hepatocellular Carcinoma is Associated with Gut Microbiota Profile and Inflammation in Non-Alcoholic Fatty Liver Disease.
Cigarette smoking is a risk factor for the onset of fatty liver disease in nondrinkers: A longitudinal cohort study
Efficacy, safety, and tolerability of lubiprostone for the treatment of non-alcoholic fatty liver disease in adult patients with constipation: The LUBIPRONE, double-blind, randomised, placebo-controlled study design.
Brown adipose tissue derived ANGPTL4 controls glucose and lipid metabolism and regulates thermogenesis.
Metabolomics profiling of steatosis progression in HepaRG® cells using sodium valproate.
Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis.
Analytical, anthropometric and dietary factors associated with the development of fibrosis in patients with nonalcoholic fatty liver disease.
Combination of NAFLD Fibrosis Score and liver stiffness measurement for identification of moderate fibrosis stages (II & III) in non-alcoholic fatty liver disease.
Canakinumab for secondary prevention of atherosclerotic disease.
ANGPTL-8/betatrophin Correlated with Hepatocellular Lipid Content Independent of Insulin Resistance in Nonalcoholic Fatty Liver Disease Subjects.